Cabergoline has halved the occurrence of tumours in mice and is associated with a lower risk in medical records of more than 150,000 women in Spain and Norway
A study published on October 15, 2026 associated cabergoline with 70% less risk of breast cancer in women in Spain and Norway. It still requires clinical trials.